Vaccine technology developed by OHSU scientists acquired by industry leaders

Biotech acquisition is key step in bringing life-saving vaccines to market

By Ariane Le Chevallier January 25, 2017 Portland, Ore.

Downloads

Louis Picker, M.D., of the Vaccine and Gene Therapy Institute at Oregon Health & Science University, June 29, 2016. (OHSU/Boone Speed Photography)

VGTI

(Left to right) Sjoerd Van Den Worm, Wilma Perez and Geoffrey Diemer, the team of scientists at the Vaccine and Gene Therapy Institute who are generating the CMV-based HIV vaccine for clinical testing. (OHSU)

OHSU Picker VGTI

Louis Picker, M.D., of the Vaccine and Gene Therapy Institute at Oregon Health & Science University (left) speaks with Scott Hansen, Ph.D., June 29, 2016.
(OHSU/Boone Speed Photography)

OHSU Picker VGTI

Researchers process blood samples in Dr. Louis Picker’s lab. (OHSU/Boone Speed Photography)

Louis Picker, M.D.

Louis J. Picker, M.D., associate director of the OHSU Vaccine and Gene Therapy Institute and professor of pathology, molecular microbiology and immunology in the OHSU School of Medicine. (OHSU)

Scott Hansen, Ph.D.

Scott Hansen, Ph.D., an assistant scientist at the OHSU Vaccine and Gene Therapy Institute and associate professor

in the OHSU School of Medicine. (OHSU)

Klaus Frueh, Ph.D.

Klaus Frueh, Ph.D., senior scientist at the OHSU Vaccine and Gene Therapy Institute and

professor for molecular microbiology and immunology in the OHSU School of Medicine. (OHSU)

Jay Nelson, Ph.D.

Jay Nelson, Ph.D., founder and director of the OHSU Vaccine and Gene Therapy Institute, senior scientist at the Oregon National Primate Research Center, and professor of molecular microbiology and immunology in the OHSU School of Medicine. (OHSU)